Intravascular lithotripsy for treatment of calcific coronary lesions in ST elevation myocardial infarction

• Published in: Catheterization and cardiovascular interventions Vol. 99; no. 2; pp. 322 - 328
• Main Authors: Cosgrove, Claudia, Hanratty, Colm G, Hill, Jonathan M, Mahadevan, Kalaivani, Mailey, Jonathan, McEntegart, Margaret, O'Kane, Peter, Sidik, Novalia, Strange, Julian W, Walsh, Simon J, Wilson, Simon, Yeoh, Julian, Spratt, James C
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2022
• Subjects: calcium; Cardiovascular disease; Coronary artery; coronary artery disease; Heart attacks; Heart diseases; Humans; Implants; Lesions; Lithotripsy; Lithotripsy - adverse effects; Lithotripsy - methods; Myocardial infarction; Patients; percutaneous coronary intervention; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - methods; Retrospective Studies; ST elevation myocardial infarction; ST Elevation Myocardial Infarction - diagnostic imaging; ST Elevation Myocardial Infarction - therapy; Stents; Thrombosis; Treatment Outcome; Vascular Calcification - diagnostic imaging; Vascular Calcification - therapy; coronary artery disease; percutaneous coronary intervention; calcium; ST elevation myocardial infarction
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.29801

Aims To describe the utility and safety of intravascular lithotripsy (IVL) in the setting of primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI). Methods and results We performed a retrospective analysis, across six UK sites of all patients in whom IVL was used for coronary calcium modification of the culprit lesion during primary PCI for STEMI. The 72 patients were included. IVL was used in de‐novo culprit lesions in 57 (79%) of cases and culprit in‐stent restenoses in 11 (15%) of cases. In four cases (6%) it was used in a newly deployed stent when this was under‐expanded due to inadequate calcium modification. Of the 30 cases in which intracoronary imaging was available for stent analysis, the average stent expansion was 104%. Intra‐procedural stent thrombosis occurred in one case (1%), and no‐reflow in three cases (4%). The 30 day MACE rates were 18%. Conclusion IVL appears to be feasible and safe for use in the treatment of calcific coronary artery disease in the setting of STEMI.